GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » PS Ratio

Liquidia (Liquidia) PS Ratio : 48.25 (As of May. 03, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Liquidia PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Liquidia's share price is $12.98. Liquidia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.27. Hence, Liquidia's PS Ratio for today is 48.25.

The historical rank and industry rank for Liquidia's PS Ratio or its related term are showing as below:

LQDA' s PS Ratio Range Over the Past 10 Years
Min: 6.54   Med: 23.45   Max: 198.89
Current: 48.93

During the past 8 years, Liquidia's highest PS Ratio was 198.89. The lowest was 6.54. And the median was 23.45.

LQDA's PS Ratio is ranked worse than
78.82% of 996 companies
in the Biotechnology industry
Industry Median: 9.035 vs LQDA: 48.93

Liquidia's Revenue per Sharefor the three months ended in Dec. 2023 was $0.07. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.27.

Warning Sign:

Liquidia Corp revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Liquidia was 3.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 130.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was -2.20% per year.

During the past 8 years, Liquidia's highest 3-Year average Revenue per Share Growth Rate was 130.40% per year. The lowest was -70.40% per year. And the median was -15.80% per year.

Back to Basics: PS Ratio


Liquidia PS Ratio Historical Data

The historical data trend for Liquidia's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia PS Ratio Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial 9.79 134.09 18.80 24.41 44.72

Liquidia Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.41 26.17 28.55 22.40 44.72

Competitive Comparison of Liquidia's PS Ratio

For the Biotechnology subindustry, Liquidia's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's PS Ratio distribution charts can be found below:

* The bar in red indicates where Liquidia's PS Ratio falls into.



Liquidia PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Liquidia's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=12.98/0.269
=48.25

Liquidia's Share Price of today is $12.98.
Liquidia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Liquidia  (NAS:LQDA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Liquidia PS Ratio Related Terms

Thank you for viewing the detailed overview of Liquidia's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia (Liquidia) Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Executives
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs director
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880